[18] [15] While the medication has demonstrated significant efficacy in glycemic control and weight reduction, patients may experience local injection site reactions, though these are less common than gastrointestinal adverse effects
3 Emerging research suggests GLP-1 medications may be particularly effective for menopause weight gain: A 2025 study presented at the Menopause Society meeting found that postmenopausal women on hormone replacement therapy (HRT) lost 19.9 percent of their body weight on tirzepatidesignificantly more than the 15.6 percent loss seen in postmenopausal women not using HT
Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Brain fog does not appear in the MHRA-approved Summary of Product Characteristics as an established adverse effect Potential mechanisms include blood glucose fluctuations, reduced caloric intake, gastrointestinal symptoms affecting nutrition and sleep, or central nervous system effects Management strategies include optimising nutrition and hydration, monitoring glucose levels, prioritising sleep, and following gradual dose titration Patients should seek medical advice for severe, worsening, or persistent cognitive symptoms, or if experiencing signs of hypoglycaemia or dehydration All suspected adverse effects should be reported through the MHRA Yellow Card Scheme to support ongoing pharmacovigilance Table of Contents Understanding Mounjaro and Its Mechanism of Action Brain Fog as a Potential Side Effect: What the Evidence Shows Why Mounjaro Might Contribute to Cognitive Symptoms Managing and Reducing Brain Fog While Taking Mounjaro When to Seek Medical Advice About Cognitive Changes Scientific References Frequently Asked Questions Understanding Mounjaro and Its Mechanism of Action Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus
About Brello Health Brello Health is a newer telehealth company founded in 2023 that focuses on making weight management more affordable and accessible
patients should report palpitations or persistent tachycardia Mood changes : Monitor for new or worsening depression or suicidal thoughts
